Parkinson disease (PD) is one of the most common age-related neurodegenerative diseases associated with motor deficiencies in humans. The symptoms are caused by the death of dopaminergic neurons in the brain, which is accompanied by the misfolding and aggregation of the protein α-synuclein. Diagnosis is based on the incidence of clinical symptoms, although they only appear as a result of the irreversible damage of neurons during the disease. Identification of a suitable biomarker would allow preclinical diagnosis. We an approach to quantify single α-synuclein aggregates as a possible biomarker for PD.
Get full access to this article
View all access options for this article.
References
1.
JankovicJ. Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry, 2008; 79:368–376.
2.
FahnS. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci, 2003; 991:1–14.
3.
BraakH, Del TrediciK, RübU, de VosRAI, Jansen SteurENH, BraakE. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 2003; 24:197–211.
BabaM, NakajoS, TuPH, TomitaT, NakayaK, LeeVM, TrojanowskiJQ, IwatsuboT. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol, 1998; 152:879–884.
6.
SpillantiniMG, CrowtherRA, JakesR, HasegawaM, GoedertM. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA, 1998; 95:6469–6473.
7.
PolymeropoulosMH, LavedanC, LeroyE, IdeSE, DehejiaA, DutraA, PikeB, RootH, RubensteinJ, BoyerR, StenroosES, ChandrasekharappaS, AthanassiadouA, PapapetropoulosT, JohnsonWG, LazzariniAM, DuvoisinRC, Di IorioG, GolbeLI, NussbaunRL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997; 276:2045–2047.
8.
KrügerR, KuhnW, MüllerT, WoitallaD, GraeberM, KöselS, PrzuntekH, EppienJT, ScholsL, RiessO. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet, 1998; 18:106–108.
9.
ZarranzJJ, AlegreJ, Gómez-EstebanJC, LezcanoE, RosR, AmpueroI, VidalL, HoenickaJ, RodriguezO, AtaresB, LlorensV, Gomez TortosaE, de SertT, MunozDG, de YebenesJG. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol, 2004; 55:164–173.
10.
HoyerW, AntonyT, ChernyD, HeimG, JovinTM, SubramaniamV. Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol, 2002; 322:383–393.
11.
LeVineH. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution. Prot Sci, 1993; 2:404–410.
12.
BirkmannE, HenkeF, WeinmannN, DumpitakC, GroschupM, FunkeA, WillboldD, RiesnerD. Counting of single prion particles bound to a capture-antibody surface (surface-FIDA)Vet Microbiol, 2007; 123:294–304.
13.
ImageJ Software. http://rsbweb.nih.gov/ij/.
14.
JanissenR, OberbarnscheidtL, OesterheltF. Optimized straight forward procedure for covalent surface immobilization of different biomolecules for single molecule applications. Colloids Surf B Biointerfaces, 2009; 71:200–207.
15.
MollenhauerB, El-AgnafOMA, MarcusK, TrenkwalderC, SchlossmacherMG. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: Review of the literature and considerations for future studies. Biomark Med, 2010; 4:683–699.
16.
TokudaT, QureshiMM, ArdahMT, VargheseS, ShehabSAS, KasaiT, IshigamiN, TamaokaA, NakagawaM, El-AgnafOM. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology, 2010; 75:1766–1772.
